Business Context and Reporting Period
This Form 8-K Current Report was filed by Gemini Therapeutics, Inc. (formerly FS Development Corp.) on February 23, 2021, covering events occurring on February 17, 2021. The filing details the appointment of Brian Piekos as the Company's Chief Financial Officer, principal accounting officer, and principal financial officer, effective February 17, 2021, succeeding Gregg Beloff.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the leadership transition in the finance function. Brian Piekos, formerly Executive Vice President, Chief Financial Officer, and Treasurer at AMAG Pharmaceuticals, has assumed the role of CFO. The filing outlines the specific compensation package negotiated for this appointment.
Guidance, Outlook, and Compensation Details
The filing provides no financial guidance or outlook. It details the following compensation terms for Mr. Piekos:
- Base Salary: $405,000 annually, subject to periodic review.
- Annual Bonus: Targeted at 40% of the annual base salary.
- Equity Grants:
- 43,580 stock options under the 2021 Stock Option and Incentive Plan (25% vesting after one year, remainder quarterly over 12 quarters).
- 377,734 shares under the 2021 Inducement Plan (25% vesting after one year, remainder monthly over 12 quarters).
- Severance (Without Cause/Good Reason): Nine months of base salary, pro-rated target bonus, and COBRA premiums.
- Change in Control Severance: Lump sum equal to one times (Base Salary + Target Bonus), full acceleration of time-based equity, and 12 months of COBRA premiums.
Investor Verification Checklist
- Verify the full text of the Employment Agreement when filed as an exhibit to the 10-Q for the period ended March 31, 2021.
- Confirm the vesting start date for equity grants is February 4, 2022.
- Review the Company's 2021 Stock Option and Incentive Plan and 2021 Inducement Plan to ensure sufficient shares/options are available for the grants described.
- Monitor future filings for any changes to the compensation committee's approval of the bonus programs.